Bruzzone M, Chiara S, Falcone A, Graziani G, Conte P F, Rosso R
Chemioterapia. 1987 Apr;6(2):137-9.
Fifteen patients with advanced epithelial ovarian cancer were treated with 4-demethoxydaunorubicin (IMI-30) after platinum failure. A total of 33 courses of IMI-30 15 mg/m2, per os, daily for 3 consecutive days every 3 weeks were performed. Three patients experienced severe hematologic toxicity (WHO grade greater than or equal to 3), while gastroenteric toxicity was acceptable and no cardiotoxicity was observed. One minor response, 4 stabilization of disease and 7 progression were observed in 12 evaluable patients. In conclusion, IMI-30, at this scheduling, is inactive in our small series of heavily pretreated epithelial ovarian cancer patients.
15例晚期上皮性卵巢癌患者在铂类治疗失败后接受了4-去甲氧柔红霉素（IMI-30）治疗。共进行了33个疗程的IMI-30治疗，剂量为15 mg/m²，口服，每3周连续3天每日给药。3例患者出现严重血液学毒性（世界卫生组织分级大于或等于3级），而胃肠道毒性可接受，未观察到心脏毒性。在12例可评估患者中，观察到1例轻微缓解、4例疾病稳定和7例疾病进展。总之，在我们这一小系列经过大量预处理的上皮性卵巢癌患者中，按照这种给药方案，IMI-30无活性。
